Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine a in rats and dogs

Archives of Pharmacal Research

Volumn 35, Issue 10, 2012, Pages 1831-1837

  Lee, Joo Hyun ^a   Shin, Yong Jun ^a   Oh, Ju Hee ^a   Lee, Young Joo ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Clopidogrel; Dog; Drug interaction; Interspecies difference; P glycoprotein; Rat

Indexed keywords

CARBOXYLIC ACID; CLOPIDOGREL; CLOPIDOGREL CARBOXYLIC ACID; CYCLOSPORIN A; GLYCOPROTEIN P INHIBITOR; PLATLESS; QUERCETIN; TELMISARTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EXPERIMENTAL DOG; EXPERIMENTAL MODEL; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SPECIES DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BENZIMIDAZOLES; BENZOATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DOGS; DRUG INTERACTIONS; FEMALE; P-GLYCOPROTEIN; PLATELET AGGREGATION INHIBITORS; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TICLOPIDINE;

EID: 84872115999     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-1017-7     Document Type: Article

References (35)

1. Chiou, W. L., Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm., 6, 539-546 (1978).
2. Dong, J., Yu, X., Wang, L., Sun, Y. B., Chen, X. J., and Wang, G. J., Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats. Acta Pharmacol. Sin., 29, 1247-1252 (2008).
3. Farid, N. A., Mcintosh, M., Garofolo, F., Wong, E., Shwajch, A., Kennedy, M., Young, M., Sarkar, P., Kawabata, K., Takahashi, M., and Pang, H., Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom., 21, 169-179 (2007a).
4. Farid, N. A., Payne, C. D., Small, D. S., Winters, K. J., Ernest, C. S., 2nd, Brandt, J. T., Darstein, C., Jakubowski, J. A., and Salazar, D. E., Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther., 81, 735-741 (2007b).
5. Gibaldi, M. and Perrier, D., Pharmacokinetics, New York, Marcel-Dekker, (1982).
6. Glaeser, H., Importance of P-glycoprotein for drug-drug interactions. Handb. Exp. Pharmacol., 201, 285-297 (2011).
7. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H. P., Von Richter, O., Zundler, J., and Kroemer, H. K., The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest., 104, 147-153 (1999).
8. Hagihara, K., Kazui, M., Ikenaga, H., Nanba, T., Fusegawa, K., Takahashi, M., Kurihara, A., Okazaki, O., Farid, N. A., and Ikeda, T., Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. Xenobiotica, 39, 218-226 (2009).
9. He, L. and Liu, G. Q., Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacol. Sin., 23, 591-596 (2002).
10. He, Y. Q., Yang, L., Liu, Y., Zhang, J. W., Tang, J., Su, J., Li, Y. Y., Lu, Y. L., Wang, C. H., and Wang, Z. T., Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry. Acta Pharmacol. Sin., 30, 1462-1470 (2009).
11. IMS. Top Ten Global Products - 2007. Cited 2011 Aug 11. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/Top10GlobalProducts.pdf.
12. Jantan, I., Yasin, Y. H. M., Jalil, J., Murad, S., and Idris, M. S., Antiplatelet aggregation activity of compounds isolated from Guttiferae species in human whole blood. Pharm. Biol., 47, 1090-1095 (2009).
13. Juliano, R. L. and Ling, V., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455, 152-162 (1976).
14. Kitamura, Y., Koto, H., Matsuura, S., Kawabata, T., Tsuchiya, H., Kusuhara, H., Tsujimoto, H., and Sugiyama, Y., Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. Drug Metab. Dispos., 36, 807-810 (2008).
15. Lan, K., He, J. L., Tian, Y., Tan, F., Jiang, X. H., Wang, L., and Ye, L. M., Intra-herb pharmacokinetics interaction between quercetin and isorhamentin. Acta Pharmacol. Sin., 29, 1376-1382 (2008).
16. Lassoued, M. A., Sfar, S., Bouraoui, A., and Khemiss, F., Absorption enhancement studies of clopidogrel hydrogen sulphate in rat everted gut sacs. J. Pharm. Pharmacol., 64, 541-552 (2012).
17. Lee, J. H., Kang, H. E., and Lee, M. G., Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats. Xenobiotica, 40, 217-224 (2010).
18. Li, P., Callery, P. S., Gan, L. S., and Balani, S. K., Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab. Dispos., 35, 1203-1208 (2007).
19. Lu, Y. L., He, Y. Q., Wang, M., Zhang, L., Yang, L., Wang, Z. T., and Ji, G., Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases in liver microsomes from humans and animals. Acta Pharmacol. Sin., 31, 1635-1642 (2010).
20. Martignoni, M., Groothuis, G. M., and De Kanter, R., Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol., 2, 875-894 (2006).
21. Morjani, H. and Madoulet, C., Immunosuppressors as multidrug resistance reversal agents. Methods Mol. Biol., 596, 433-446 (2010).
22. Savi, P. and Herbert, J. M., Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin. Thromb. Hemost., 31, 174-183 (2005).
23. Scambia, G., Ranelletti, F. O., Panici, P. B., De Vincenzo, R., Bonanno, G., Ferrandina, G., Piantelli, M., Bussa, S., Rumi, C., Cianfriglia, M., and Mancuso, S., Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol., 34, 459-464 (1994).
24. Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., and Becquemont, L., Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med., 360, 363-375 (2009).
25. Stangier, J., Su, C. A., Hendriks, M. G., Van Lier, J. J., Sollie, F. A., Oosterhuis, B., and Jonkman, J. H., The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J. Clin. Pharmacol., 40, 1373- 1379 (2000).
26. Suzuyama, N., Katoh, M., Takeuchi, T., Yoshitomi, S., Higuchi, T., Asashi, S., and Yokoi, T., Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J. Pharm. Sci., 96, 1609-1618 (2007).
27. Tahara, H., Kusuhara, H., Fuse, E., and Sugiyama, Y., P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab. Dispos., 33, 963-968 (2005).
28. Taketani, M., Shii, M., Ohura, K., Ninomiya, S., and Imai, T., Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci., 81, 924-932 (2007).
29. Tang, M., Mukundan, M., Yang, J., Charpentier, N., Lecluyse, E. L., Black, C., Yang, D., Shi, D., and Yan, B., Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther., 319, 1467-1476 (2006).
30. Taubert, D., Von Beckerath, N., Grimberg, G., Lazar, A., Jung, N., Goeser, T., Kastrati, A., Schomig, A., and Schomig, E., Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther., 80, 486-501 (2006).
31. Thrift, A. G., Mcneil, J. J., Forbes, A., and Donnan, G. A., Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension, 31, 1223-1229 (1998).
32. Umathe, S. N., Dixit, P. V., Kumar, V., Bansod, K. U., and Wanjari, M. M., Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition. Biochem. Pharmacol., 75, 1670-1676 (2008).
33. Wang, Y. H., Chao, P. D., Hsiu, S. L., Wen, K. C., and Hou, Y. C., Lethal quercetin-digoxin interaction in pigs. Life Sci., 74, 1191-1197 (2004).
34. Weiss, J., Sauer, A., Divac, N., Herzog, M., Schwedhelm, E., Boger, R. H., Haefeli, W. E., and Benndorf, R. A., Interaction of angiotensin receptor type 1 blockers with ATPbinding cassette transporters. Biopharm. Drug Dispos., 31, 150-161 (2010).
35. Williams, E. T., Jones, K. O., Ponsler, G. D., Lowery, S. M., Perkins, E. J., Wrighton, S. A., Ruterbories, K. J., Kazui, M., and Farid, N. A., The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab. Dispos., 36, 1227-1232 (2008).